⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8401086 | 1.00 | — | — | |
| SCHEMBL12702372 | 1.00 | — | — | |
| SCHEMBL17124634 | 1.00 | — | — | |
| SCHEMBL12723620 | 1.00 | — | — | |
| SCHEMBL14327259 | 1.00 | — | — | |
| SCHEMBL13207481 | 0.83 | NOS3 (0.32) | — | |
| SCHEMBL2611670 | 0.83 | NOS3 (0.32) | — | |
| SCHEMBL12715769 | 0.82 | — | — | |
| SCHEMBL7020593 | 0.82 | — | — | |
| SCHEMBL7022461 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | SENDA BIOSCIENCES, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| EP-3746435-B1 | SUBSTITUTED QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-3746435-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| US-10662204-B2 | Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-05-26 | — | — | US | disclosed |
| WO-2019150305-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| US-20190233440-A1 | Substituted Quinazoline and Pyridopyrimidine Derivatives Useful as Anticancer Agents | PFIZER INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-8404862-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| EP-2537845-A1 | 6H-dibenzo[B,E]oxepine derived nonsteroidal mineralocorticoid receptor antagonists | Eli Lilly and Company (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2235007-B1 | 6H-DIBENZ0 [B, E] OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20100069471-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009085584-A1 | 6H-DIBENZ0 [B, E] OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2009-07-09 | — | — | WO | disclosed |